TKTae Kon Kim

Tae Kon Kim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tae Kon Kim has a total of 353 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Aligning Clinical Trial Reporting: A systematic analysis and position statement by the International Consortium for MDS

    by Andrew M. Brunner, Ted M. Getz, Kelly Pugh, Jan Philipp Bewersdorf, Tariq Kewan, Uma Borate, Amy E DeZern, Uwe Platzbecker, Mikkael A Sekeres, Andrew H Wei, et al.

    Variability in how clinical trial elements are reported can hinder accurate interpretation and comparison of trial results. Here, we systematically analyzed published manuscripts of therapeutic clinical trials in myelodysplastic syndromes/neoplasms (MDS) focusing on how key data elements were reported and made recommendations on how to improve this reporting. We included peer-reviewed full text manuscripts that reported results of clinical trials in MDS and were published between January 1, 2015 to December 31, 2024. We analyzed the presence or absence of several pre-determined key reporting elements and then synthesized these data to evaluate for consistency across manuscripts. We identified substantial variability in descriptions of patient characteristics, as well as the definitions used for response criteria. For example, baseline ANC was reported in only 16% of lower-risk MDS studies and 23% of higher-risk MDS studies, while baseline bone marrow blast percentage was reported in only 55% of higher-risk MDS manuscripts. In addition, response endpoints lacked standardization, with six unique definitions of RBC transfusion independence identified in lower-risk MDS trials and seven different definitions of overall response rate identified in higher-risk MDS trials. Informed by the results of this analysis, we then performed a modified-Delphi process for members of the International Consortium for MDS (icMDS) to develop consensus-based recommendations for consistent and accurate reporting of MDS clinical trial results. We advocate that these recommendations serve as benchmarks and templates for clinical trial reporting in MDS to improve interpretability and comparison of results.

  • Open Access

    Is Pseudo-progression post-CAR T therapy real?

    by Alicia Shin, Kian Rahbari, Wichai Chinratanalab, Bipin Savani, Adetola Kassim, James Jerkins, Bhagirathbhai Dholaria, Lindsay Orton, Rachel Gilmore, Kendall Shultes, et al.

  • Outcomes of hematopoietic stem cell transplantation in patients aged 70 years and older

    by Rachel B. Gorham, Salyka Sengsayadeth, Christina A. Snider, Chiu-Lan Chen, Eden Ayele Biltibo, Wichai Chinratanalab, Bhagirathbhai Dholaria, Andrew P. Jallouk, James H. Jerkins, Adetola A. Kassim, et al.

  • Open Access

    VISTA mediates the progression of myelodysplastic syndrome

    by Raymond J. Zhang, Hyundong Yoon, Qianni Hu, Carly M. Fielder, Anjali Raman, Emily F. Mason, Haley E. Ramsey, Agnieszka E. Gorska, David Zhang, Carlos H. Serezani, et al.

    Myelodysplastic syndrome (MDS) is characterized by progressive cytopenias and a substantial risk of transformation to acute myeloid leukemia. Immune dysregulation is central to the pathogenesis of MDS, and immune suppression is often associated with disease progression. However, immunotherapies such as anti-programmed cell death protein-1 therapy have shown limited efficacy in patients, indicating an incomplete understanding of immune suppression in MDS. To better characterize the immune features of MDS, we performed extensive immune phenotyping of MDS patient bone marrow (BM). We demonstrate that V-domain Ig suppressor of T cell activation (VISTA), an inhibitory immune checkpoint, is upregulated in MDS patients by CD34+ blasts and granulocytic myeloid-derived suppressor cells (G-MDSCs) compared to healthy controls, and G-MDSC VISTA expression positively correlates with T cell suppression. In studies employing the NUP98-HOXD13 transgenic MDS mouse model, genetic deletion of VISTA delays the progression of anemia and decreases the rate of death due to severe cytopenias. Assessment of MDS mice reveals that VISTA deletion reduces BM populations of G-MDSCs and reverses the suppression of T cells and macrophages. Together, our findings suggest that VISTA may augment G-MDSC-mediated immune suppression and significantly contribute to ineffective hematopoiesis in MDS.

  • Outpatient Administration of Bispecific Antibody Therapy for Hematologic Malignancies: A Practical Guide

    by Kian J. Rahbari, Raul del Toro Mijares, Kathryn Kennedy, Leslie Mader, Salyka Sengsayadeth, Reena V. Jayani-Kosarzycki, James Jerkins, Andrew Jallouk, Tae Kon Kim, Shakthi Bhaskar, et al.

    Bispecific antibodies (BsAbs) are currently used to treat hematologic malignancies by cross-linking cytotoxic T cells with tumor cells and thus stimulating cellular immunity. Hyperactivation of T cells leads to dysregulated cytokine release, which causes the chief toxicities of BsAbs, cytokine release syndrome (CRS) and immune effector cell–mediated neurotoxicity syndrome (ICANS). On the basis of clinical trial experiences, standard practice is to hospitalize patients for intensive monitoring during periods when the risk of CRS and ICANS is highest. A strategy to safely administer these medications outpatient would improve patient access and reduce health care–associated costs. The lessons learned from outpatient administration of chimeric antigen receptor T cell therapy (CAR-T) may be applied to BsAbs given overlapping toxicity profiles. Outpatient delivery of BsAbs is feasible but requires a specialized multidisciplinary team, a robust infrastructure with well-defined standard procedures, and significant patient support and education. Emerging clinical practices, including prophylactic anti-inflammatory therapy and modified dosing schedules, further facilitate safe outpatient administration.


  • Open Access

    Systemic chemotherapy in metastatic TNBC polarizes effector T cell differentiation

    by Hye-Yeon Ju, Hyundong Yoon, Seungpil Jung, Serk In Park, Tae Kon Kim, Mi-Ryung Han

    Triple-negative breast cancer (TNBC) has the poorest prognosis among the three major subtypes of breast cancer, and more than one-third of patients with TNBC experience recurrence or distant metastasis. Despite advances in diverse immunotherapy strategies for metastatic TNBC (mTNBC), multiple mechanisms underlying resistance to treatment remain unknown. In this study, the dynamic changes in the immune landscape in mTNBC were assessed and compared with healthy donors using single-cell RNA sequencing (scRNA-seq) analysis. By integrating internal and public scRNA-seq data, 61,149 cells extracted from East Asian patients with mTNBC and 51,448 cells extracted from East Asian healthy donors were used to landscape a comprehensive cellular profile of mTNBC. Results showed that nine overexpressed genes from patients with mTNBC in effector T cells such as CTSW, PRF1, GNLY, GZMA, CCL5, KLRD1, KLRB1, B2M, and GZMB exhibited favorable survival prognoses. In addition, effector T cells enriched in patients with mTNBC were more differentiated compared with those enriched in healthy donors. Collectively, this study is the first to provide potential diagnostic and therapeutic targets of East Asian chemotherapy-treated mTNBC with regard to effector T cells.

  • Targeting cell-surface VISTA expression on allospecific naïve T cells promotes tolerance

    by Brent H. Koehn, Elizabeth C. Nowak, Sladjana Skopelja-Gardner, Asim Saha, Michael C. Zaiken, Jeremy Allred, Yiyung Peng, Wilson L. Davis, Isabelle Le Mercier, Nicholas Schwertner, et al.

    The success of allogeneic hematopoietic stem cell transplantation (allo-HSCT) can be limited by graft-versus-host disease (GVHD). T-cell activation is a key factor in GVHD progression. Costimulatory signals can be counterbalanced by coinhibitory signals such as the checkpoint molecule VISTA (V-domain immunoglobulin-containing suppressor of T-cell activation)/programmed death-1 homolog that restrains activation and maintains donor T-cell quiescence. A single dose of anti-VISTA monoclonal antibody (mAb) prevents acute GVHD lethality in multiple models. Naïve donor T cells express moderate VISTA levels, which transiently increase in allo-HSCT recipients in association with T-cell receptor signaling, leading to heightened susceptibility to anti-VISTA mAb–mediated depletion, in contrast to donor T cells transferred to syngeneic recipients. Anti-VISTA mAb donor T-cell depletion was compatible with rapamycin but incompatible with peritransplant tacrolimus GVHD prophylaxis. Targeting VISTA exclusively on host cells or donor CD8+ T cells was not protective against GVHD lethality. Instead, anti-VISTA mAb–mediated deletion of alloreactive donor T cells depended on targeting a third (non-T) cell type. Further mechanistic studies indicated that donor T cells concurrently exposed to anti-VISTA mAb in vivo but not preincubated in vitro before adoptive T-cell transfer were eliminated via Fc receptor (FcR)-mediated phagocytosis. In a lymphoma challenge model, a graft-versus-lymphoma (GVL) effect was fully retained when anti-human VISTA mAb exclusively targeted donor CD4+ T cells, and was delayed but mostly retained when unseparated donor T cells were infused. In a xenogeneic GVHD model, anti-human VISTA mAb reduced donor T-cell expansion, VISTA T-cell expression levels, and recipient lethality. Together, these data support a novel clinical translational pathway in which acute GVHD lethality can be mitigated without negating the GVL effect.


  • Open Access

    Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement

    by Uma Borate, Kelly Pugh, Allyson Waller, Rina Li Welkie, Ying Huang, Jan Philipp Bewersdorf, Maximilian Stahl, Amy E. DeZern, Uwe Platzbecker, Mikkael A. Sekeres, et al.

    Excessively restrictive inclusion and exclusion criteria in clinical trials are one of many barriers to clinical trial enrollment for patients with myelodysplastic syndromes/neoplasms (MDSs). Many organizations are developing efforts to increase clinical trial eligibility; yet, several recent publications focused on patients with MDS suggest that many patients with this disease may be excluded from clinical trials unnecessarily. Clinical trial eligibility should reflect the phase of the study and risks of the agent being studied. Phase 3 trials should be less restrictive than early-phase trials to represent the real-world population as closely as possible. We hypothesize that many clinical trials, particularly phase 3 trials, have unnecessarily restrictive eligibility criteria. This study aims to evaluate the most common eligibility criteria according to phase of trial and to determine whether criteria correspond with drug safety signals. We identified MDS clinical trials registered on ClinicalTrials.gov from 1 January 2000 to 1 September 2023 and analyzed the eligibility criteria of 191 therapeutic MDS trials. We found that categorical inclusion and exclusion criteria are remarkably similar in representation across trial phases. Additionally, only 13% of trials are concordant with drug safety signals, suggesting that the eligibility criteria are often arbitrary. On behalf of the icMDS (International Consortium for Myelodysplastic Syndromes), an association of international MDS experts, we provide a position statement on restrictive eligibility criteria for MDS clinical trials that should be avoided with the aim of removing barriers to clinical trial enrollment.


  • Open Access

    VISTA-mediated immune evasion in cancer

    by Raymond J. Zhang, Tae Kon Kim

    Over the past decade, V-domain immunoglobulin suppressor of T-cell activation (VISTA) has been established as a negative immune checkpoint molecule. Since the role of VISTA in inhibiting T-cell activation was described, studies have demonstrated other diverse regulatory functions in multiple immune cell populations. Furthermore, its relevance has been identified in human cancers. The role of VISTA in cancer immune evasion has been determined, but its mechanisms in the tumor microenvironment remain to be further elucidated. Understanding its contributions to cancer initiation, progression, and resistance to current treatments will be critical to its utility as a target for novel immunotherapies. Here, we summarize the current understanding of VISTA biology in cancer.


  • Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes

    by Rami S Komrokji, Luca Lanino, Somedeb Ball, Jan P Bewersdorf, Monia Marchetti, Giulia Maggioni, Erica Travaglino, Najla H Al Ali, Pierre Fenaux, Uwe Platzbecker, et al.